Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

The KDIGO 2025 guideline update for IgA nephropathy and IgA vasculitis encourages a more liberal kidney biopsy policy, sets stricter proteinuria targets (< 0.5 g/d, ideally < 0.3 g/d), and introduces a dual treatment strategy that both reduces pathogenic IgA and manages the consequences of nephron loss.